Initial symptoms included progressive hepatic failure detected. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
A medical history of persistent depletion of mitochondrial dna in liver observed, progressive cerebral cortical atrophy was documented. Genetic analysis confirmed gene variant p.W748S and p.T914P. Supportive care and follow-up were recommended.
The individual was admitted with complaints of focal motor status epilepticus observed, chronic unsteady gait detected. Laboratory evaluations detected gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Clinical monitoring is ongoing.
The patient presented to the clinic with diagnosed with sudden unsteady gait, chronic ptosis manifestation. Diagnostic workup revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Treatment was initiated accordingly.
Upon examination, episodic focal motor status epilepticus, history of depletion of mitochondrial dna in liver, history of progressive cerebellar atrophy, ptosis condition were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of moderate cerebral cortical atrophy condition, presence of severe ptosis, sudden unsteady gait observed. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
The patient presented to the clinic with clinical signs of persistent depletion of mitochondrial dna in liver, presence of unsteady gait, persistent focal motor status epilepticus condition, moderate postural instability observed. Diagnostic workup revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Treatment was initiated accordingly.
A medical history of persistent focal motor status epilepticus symptoms, persistent ptosis symptoms, presence of hepatic failure was documented. Genetic analysis confirmed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Supportive care and follow-up were recommended.
The patient presented to the clinic with intermittent cerebellar atrophy condition, chronic ptosis observed, intermittent conjugated hyperbilirubinemia condition. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
The individual was admitted with complaints of moderate conjugated hyperbilirubinemia condition, history of chronic ptosis, moderate focal motor status epilepticus observed, history of chronic cerebral cortical atrophy. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
The individual was admitted with complaints of moderate depletion of mitochondrial dna in liver, clinical signs of chronic cerebral cortical atrophy, severe ptosis, presence of chronic acute hepatic failure. Laboratory evaluations detected gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Clinical monitoring is ongoing.
The individual was admitted with complaints of acute acute hepatic failure condition, history of episodic cerebellar atrophy. Laboratory evaluations detected gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Clinical monitoring is ongoing.
A medical history of progressive cerebral cortical atrophy observed was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Supportive care and follow-up were recommended.
A medical history of episodic ptosis, severe cerebellar atrophy condition, presence of progressive postural instability was documented. Genetic analysis confirmed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Supportive care and follow-up were recommended.
A medical history of presence of moderate conjugated hyperbilirubinemia, history of severe focal motor status epilepticus, presence of persistent hepatic failure was documented. Genetic analysis confirmed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Supportive care and follow-up were recommended.
The patient presented to the clinic with clinical signs of persistent acute hepatic failure, severe unsteady gait manifestation, episodic cerebellar atrophy manifestation, mild depletion of mitochondrial dna in liver detected. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of moderate conjugated hyperbilirubinemia condition, episodic focal motor status epilepticus observed, presence of episodic ptosis, intermittent unsteady gait symptoms. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
The individual was admitted with complaints of severe acute hepatic failure manifestation, diagnosed with conjugated hyperbilirubinemia, persistent ptosis observed, episodic unsteady gait symptoms. Laboratory evaluations detected . Clinical monitoring is ongoing.
The patient presented to the clinic with moderate cerebral cortical atrophy condition, progressive acute hepatic failure symptoms, intermittent hepatic failure condition. Diagnostic workup revealed gene variant P765T. Treatment was initiated accordingly.
A medical history of moderate conjugated hyperbilirubinemia, progressive cerebral cortical atrophy manifestation, focal motor status epilepticus observed, clinical signs of moderate cerebellar atrophy was documented. Genetic analysis confirmed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Supportive care and follow-up were recommended.
Initial symptoms included progressive focal motor status epilepticus symptoms, history of acute conjugated hyperbilirubinemia. Subsequent investigations showed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included presence of moderate cerebral cortical atrophy, sudden conjugated hyperbilirubinemia observed, clinical signs of persistent acute hepatic failure, presence of moderate hepatic failure. Subsequent investigations showed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Management involved both pharmacological and rehabilitative approaches.
Upon examination, clinical signs of moderate cerebral cortical atrophy, mild ptosis manifestation, severe acute hepatic failure symptoms were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
A medical history of progressive conjugated hyperbilirubinemia observed, chronic cerebellar atrophy detected, chronic ptosis detected, sudden postural instability manifestation was documented. Genetic analysis confirmed gene variant c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
A medical history of sudden hepatic failure observed, history of intermittent depletion of mitochondrial dna in liver, episodic cerebral cortical atrophy manifestation, diagnosed with progressive unsteady gait was documented. Genetic analysis confirmed gene variant c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
Initial symptoms included intermittent cerebral cortical atrophy manifestation. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of episodic acute hepatic failure symptoms, chronic conjugated hyperbilirubinemia symptoms, intermittent cerebellar atrophy, sudden depletion of mitochondrial dna in liver manifestation. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
The individual was admitted with complaints of diagnosed with sudden acute hepatic failure. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
A medical history of moderate focal motor status epilepticus detected, presence of persistent conjugated hyperbilirubinemia was documented. Genetic analysis confirmed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
The individual was admitted with complaints of acute acute hepatic failure symptoms, intermittent postural instability condition, history of unsteady gait. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
Upon examination, mild hepatic failure manifestation, diagnosed with focal motor status epilepticus, diagnosed with sudden cerebellar atrophy, episodic ptosis were noted. Further imaging and laboratory tests identified gene variant c.679C>T p.R227W and c.2542G>A p.G848S. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of progressive acute hepatic failure, presence of acute cerebral cortical atrophy, persistent cerebellar atrophy condition. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
Initial symptoms included clinical signs of mild unsteady gait. Subsequent investigations showed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild focal motor status epilepticus symptoms, diagnosed with persistent conjugated hyperbilirubinemia, presence of depletion of mitochondrial dna in liver, acute unsteady gait. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Treatment was initiated accordingly.
The patient presented to the clinic with progressive postural instability. Diagnostic workup revealed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Treatment was initiated accordingly.
Initial symptoms included episodic hepatic failure detected. Subsequent investigations showed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of severe ptosis symptoms, acute hepatic failure condition, moderate depletion of mitochondrial dna in liver detected, history of mild hepatic failure. Laboratory evaluations detected gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Clinical monitoring is ongoing.
The individual was admitted with complaints of mild cerebral cortical atrophy detected, clinical signs of chronic conjugated hyperbilirubinemia, presence of severe focal motor status epilepticus. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of intermittent depletion of mitochondrial dna in liver condition, history of postural instability, clinical signs of progressive hepatic failure was documented. Genetic analysis confirmed gene variant c.2864A>G (p.Tyr955Cys). Supportive care and follow-up were recommended.
A medical history of moderate postural instability condition, chronic depletion of mitochondrial dna in liver condition was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
A medical history of acute hepatic failure observed was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
Initial symptoms included history of progressive unsteady gait, clinical signs of persistent postural instability. Subsequent investigations showed gene variant Tyr955Cys. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of sudden conjugated hyperbilirubinemia, clinical signs of episodic ptosis, progressive focal motor status epilepticus detected, presence of intermittent hepatic failure. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
The individual was admitted with complaints of mild hepatic failure observed, moderate cerebellar atrophy, persistent unsteady gait symptoms. Laboratory evaluations detected gene variant 1399G >A A467T and 2243G >C W748S. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of unsteady gait, clinical signs of severe postural instability. Diagnostic workup revealed gene variant p.Arg627Gln and p.Arg852Cys. Treatment was initiated accordingly.
Initial symptoms included intermittent cerebral cortical atrophy detected. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included chronic focal motor status epilepticus observed. Subsequent investigations showed gene variant p.Arg953Cys. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild hepatic failure observed. Diagnostic workup revealed gene variant p.A467T and c.2157+5_6GC>AG. Treatment was initiated accordingly.
The individual was admitted with complaints of history of sudden cerebellar atrophy. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
Initial symptoms included persistent hepatic failure observed. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
Upon examination, mild cerebellar atrophy manifestation, clinical signs of progressive unsteady gait, persistent ptosis were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with persistent ptosis manifestation, diagnosed with persistent cerebellar atrophy, episodic hepatic failure condition, chronic depletion of mitochondrial dna in liver manifestation. Diagnostic workup revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Treatment was initiated accordingly.
The patient presented to the clinic with persistent cerebellar atrophy symptoms, clinical signs of acute postural instability, persistent hepatic failure observed, severe ptosis manifestation. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with diagnosed with sudden depletion of mitochondrial dna in liver, diagnosed with intermittent acute hepatic failure. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The patient presented to the clinic with sudden hepatic failure condition, presence of sudden unsteady gait. Diagnostic workup revealed . Treatment was initiated accordingly.
Upon examination, ptosis, mild focal motor status epilepticus detected were noted. Further imaging and laboratory tests identified gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). The patient was started on a tailored therapeutic plan.
A medical history of severe cerebral cortical atrophy symptoms, depletion of mitochondrial dna in liver observed, severe focal motor status epilepticus observed was documented. Genetic analysis confirmed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Supportive care and follow-up were recommended.
Initial symptoms included persistent hepatic failure, moderate cerebellar atrophy, sudden focal motor status epilepticus observed. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included history of progressive cerebellar atrophy, history of severe ptosis. Subsequent investigations showed gene variant A467T. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of sudden cerebellar atrophy, moderate conjugated hyperbilirubinemia observed. Laboratory evaluations detected gene variant T251I/P587L and R807C. Clinical monitoring is ongoing.
Initial symptoms included chronic postural instability observed, acute acute hepatic failure manifestation. Subsequent investigations showed gene variant c.1288A>T and c.2752T>C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of persistent focal motor status epilepticus detected. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
A medical history of presence of mild ptosis was documented. Genetic analysis confirmed gene variant 1399G>A A467T and 3573G>T K1191N. Supportive care and follow-up were recommended.
Initial symptoms included acute postural instability observed. Subsequent investigations showed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Management involved both pharmacological and rehabilitative approaches.
Upon examination, episodic focal motor status epilepticus manifestation, history of moderate hepatic failure were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with moderate cerebral cortical atrophy. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
Initial symptoms included intermittent cerebellar atrophy. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with diagnosed with sudden cerebral cortical atrophy, moderate hepatic failure condition, mild conjugated hyperbilirubinemia symptoms. Diagnostic workup revealed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Treatment was initiated accordingly.
Upon examination, mild conjugated hyperbilirubinemia manifestation were noted. Further imaging and laboratory tests identified gene variant 1399G>A A467T and 3573G>T K1191N. The patient was started on a tailored therapeutic plan.
Upon examination, presence of episodic depletion of mitochondrial dna in liver, intermittent postural instability symptoms were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with sudden cerebral cortical atrophy condition, chronic unsteady gait manifestation. Diagnostic workup revealed gene variant 1399Gâ†’A (A467T). Treatment was initiated accordingly.
The patient presented to the clinic with acute conjugated hyperbilirubinemia observed, diagnosed with postural instability, clinical signs of acute hepatic failure. Diagnostic workup revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Treatment was initiated accordingly.
A medical history of clinical signs of mild focal motor status epilepticus, acute postural instability, diagnosed with severe cerebral cortical atrophy was documented. Genetic analysis confirmed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Supportive care and follow-up were recommended.
Initial symptoms included persistent cerebellar atrophy symptoms, severe conjugated hyperbilirubinemia detected, persistent ptosis, history of moderate focal motor status epilepticus. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of intermittent unsteady gait manifestation, chronic ptosis manifestation. Laboratory evaluations detected gene variant p.Arg627Gln and p.Arg852Cys. Clinical monitoring is ongoing.
Initial symptoms included history of intermittent ptosis, presence of persistent acute hepatic failure, conjugated hyperbilirubinemia condition, intermittent unsteady gait. Subsequent investigations showed gene variant p.Arg627Gln and p.Arg852Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of severe focal motor status epilepticus detected, chronic hepatic failure observed was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
Upon examination, chronic unsteady gait manifestation, moderate acute hepatic failure manifestation were noted. Further imaging and laboratory tests identified gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. The patient was started on a tailored therapeutic plan.
Upon examination, persistent acute hepatic failure condition, postural instability detected, history of acute hepatic failure, clinical signs of mild depletion of mitochondrial dna in liver were noted. Further imaging and laboratory tests identified gene variant p.W748S and p.T914P. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with progressive postural instability detected, mild depletion of mitochondrial dna in liver observed, history of persistent ptosis, persistent conjugated hyperbilirubinemia detected. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
A medical history of diagnosed with severe hepatic failure, acute cerebellar atrophy symptoms was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Upon examination, sudden ptosis observed were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
A medical history of history of moderate postural instability, history of episodic ptosis, sudden conjugated hyperbilirubinemia was documented. Genetic analysis confirmed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Supportive care and follow-up were recommended.
A medical history of presence of acute depletion of mitochondrial dna in liver, moderate cerebral cortical atrophy manifestation, ptosis condition was documented. Genetic analysis confirmed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Supportive care and follow-up were recommended.
Upon examination, progressive cerebral cortical atrophy condition were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
A medical history of progressive postural instability, severe hepatic failure manifestation, mild unsteady gait symptoms, diagnosed with acute depletion of mitochondrial dna in liver was documented. Genetic analysis confirmed gene variant p.A467T and c.2157+5_6GC>AG. Supportive care and follow-up were recommended.
A medical history of history of intermittent conjugated hyperbilirubinemia, history of intermittent focal motor status epilepticus, clinical signs of chronic postural instability was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
A medical history of mild ptosis observed was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
The patient presented to the clinic with severe acute hepatic failure condition. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
The patient presented to the clinic with sudden conjugated hyperbilirubinemia. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
The patient presented to the clinic with persistent unsteady gait condition, persistent acute hepatic failure symptoms, clinical signs of mild cerebellar atrophy, intermittent focal motor status epilepticus manifestation. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with severe unsteady gait, clinical signs of severe ptosis, moderate cerebral cortical atrophy observed. Diagnostic workup revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Treatment was initiated accordingly.
The individual was admitted with complaints of presence of sudden conjugated hyperbilirubinemia, depletion of mitochondrial dna in liver condition, diagnosed with sudden acute hepatic failure, severe focal motor status epilepticus detected. Laboratory evaluations detected gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Clinical monitoring is ongoing.
Upon examination, presence of mild hepatic failure, persistent unsteady gait, acute depletion of mitochondrial dna in liver detected, diagnosed with acute cerebellar atrophy were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
Initial symptoms included clinical signs of cerebellar atrophy, persistent acute hepatic failure, severe focal motor status epilepticus manifestation. Subsequent investigations showed gene variant 1399G >A A467T and 2243G >C W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of mild cerebellar atrophy detected, presence of moderate ptosis, clinical signs of acute depletion of mitochondrial dna in liver. Laboratory evaluations detected gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of progressive unsteady gait. Diagnostic workup revealed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Treatment was initiated accordingly.
Initial symptoms included presence of episodic postural instability, history of episodic cerebellar atrophy, clinical signs of chronic hepatic failure. Subsequent investigations showed gene variant c.2864A>G (p.Tyr955Cys). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with presence of episodic postural instability. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
Initial symptoms included acute hepatic failure condition, chronic cerebellar atrophy. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with sudden conjugated hyperbilirubinemia observed, severe focal motor status epilepticus detected. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
Initial symptoms included acute cerebral cortical atrophy observed, history of moderate acute hepatic failure, history of progressive unsteady gait, clinical signs of moderate depletion of mitochondrial dna in liver. Subsequent investigations showed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, severe depletion of mitochondrial dna in liver condition, presence of persistent unsteady gait, presence of sudden postural instability, persistent cerebellar atrophy manifestation were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of cerebellar atrophy, diagnosed with severe cerebral cortical atrophy, diagnosed with sudden unsteady gait. Diagnostic workup revealed gene variant 1868T>G  L623W and 2263A>G K755E. Treatment was initiated accordingly.
The patient presented to the clinic with moderate ptosis symptoms. Diagnostic workup revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Treatment was initiated accordingly.
The individual was admitted with complaints of intermittent cerebellar atrophy. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of moderate focal motor status epilepticus, persistent postural instability condition, intermittent cerebellar atrophy, presence of progressive unsteady gait. Diagnostic workup revealed gene variant W748S and c.3643+2T>C. Treatment was initiated accordingly.
Initial symptoms included intermittent hepatic failure manifestation, moderate cerebellar atrophy manifestation. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of moderate unsteady gait were noted. Further imaging and laboratory tests identified gene variant c.3643+1G>A and c.2396C>A (p.S799Y). The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of sudden depletion of mitochondrial dna in liver, conjugated hyperbilirubinemia, clinical signs of mild hepatic failure was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
A medical history of sudden focal motor status epilepticus condition, chronic cerebral cortical atrophy condition was documented. Genetic analysis confirmed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
The patient presented to the clinic with acute ptosis manifestation, presence of persistent unsteady gait, moderate cerebral cortical atrophy condition, chronic depletion of mitochondrial dna in liver symptoms. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
Initial symptoms included diagnosed with intermittent conjugated hyperbilirubinemia, severe hepatic failure. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with diagnosed with severe cerebellar atrophy. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
Initial symptoms included clinical signs of sudden depletion of mitochondrial dna in liver, intermittent focal motor status epilepticus manifestation, intermittent ptosis symptoms, progressive hepatic failure manifestation. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
A medical history of progressive unsteady gait manifestation, mild depletion of mitochondrial dna in liver manifestation, chronic ptosis was documented. Genetic analysis confirmed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Supportive care and follow-up were recommended.
Initial symptoms included focal motor status epilepticus. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Management involved both pharmacological and rehabilitative approaches.
Upon examination, intermittent cerebellar atrophy condition, persistent unsteady gait symptoms, mild ptosis observed were noted. Further imaging and laboratory tests identified gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. The patient was started on a tailored therapeutic plan.
A medical history of mild cerebellar atrophy, episodic conjugated hyperbilirubinemia, presence of moderate postural instability was documented. Genetic analysis confirmed gene variant 1399Gâ†’A (A467T). Supportive care and follow-up were recommended.
Initial symptoms included chronic depletion of mitochondrial dna in liver, clinical signs of severe focal motor status epilepticus, clinical signs of mild acute hepatic failure, acute cerebellar atrophy manifestation. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of progressive unsteady gait, episodic focal motor status epilepticus detected, severe ptosis observed. Laboratory evaluations detected gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Clinical monitoring is ongoing.
A medical history of severe depletion of mitochondrial dna in liver, clinical signs of episodic postural instability, history of episodic hepatic failure was documented. Genetic analysis confirmed gene variant 1399Gâ†’A (A467T). Supportive care and follow-up were recommended.
Initial symptoms included persistent focal motor status epilepticus detected. Subsequent investigations showed gene variant R853W and G737R. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of persistent unsteady gait, history of hepatic failure, acute ptosis detected was documented. Genetic analysis confirmed gene variant p.W748S and p.T914P. Supportive care and follow-up were recommended.
Initial symptoms included presence of progressive postural instability, clinical signs of moderate acute hepatic failure. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent cerebellar atrophy symptoms, sudden acute hepatic failure manifestation were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
Upon examination, clinical signs of acute unsteady gait, history of episodic depletion of mitochondrial dna in liver, acute postural instability symptoms were noted. Further imaging and laboratory tests identified gene variant 1399Gâ†’A (A467T). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with persistent acute hepatic failure, diagnosed with mild hepatic failure. Diagnostic workup revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Treatment was initiated accordingly.
The individual was admitted with complaints of acute unsteady gait detected, presence of hepatic failure, chronic ptosis observed, chronic acute hepatic failure condition. Laboratory evaluations detected gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Clinical monitoring is ongoing.
The individual was admitted with complaints of presence of mild hepatic failure, diagnosed with intermittent conjugated hyperbilirubinemia, intermittent focal motor status epilepticus detected. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Initial symptoms included moderate cerebellar atrophy condition, intermittent hepatic failure. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of progressive focal motor status epilepticus symptoms. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
Initial symptoms included acute conjugated hyperbilirubinemia detected, history of sudden cerebral cortical atrophy. Subsequent investigations showed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Management involved both pharmacological and rehabilitative approaches.
Upon examination, diagnosed with moderate acute hepatic failure, presence of progressive cerebellar atrophy, presence of persistent unsteady gait were noted. Further imaging and laboratory tests identified gene variant C752T (T251I) and C1760T (P587L). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with intermittent cerebellar atrophy, progressive postural instability manifestation. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
Upon examination, diagnosed with conjugated hyperbilirubinemia, severe cerebral cortical atrophy observed, mild unsteady gait condition, diagnosed with persistent focal motor status epilepticus were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
Upon examination, acute conjugated hyperbilirubinemia observed, severe cerebral cortical atrophy manifestation were noted. Further imaging and laboratory tests identified gene variant c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
A medical history of moderate hepatic failure symptoms, clinical signs of sudden acute hepatic failure, cerebellar atrophy detected was documented. Genetic analysis confirmed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Supportive care and follow-up were recommended.
The patient presented to the clinic with hepatic failure observed, clinical signs of progressive acute hepatic failure, severe focal motor status epilepticus. Diagnostic workup revealed gene variant P765T. Treatment was initiated accordingly.
Upon examination, mild unsteady gait manifestation, severe ptosis detected, moderate postural instability manifestation, presence of mild cerebellar atrophy were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild acute hepatic failure detected. Laboratory evaluations detected gene variant p.Arg627Gln and p.Arg852Cys. Clinical monitoring is ongoing.
Upon examination, history of moderate cerebellar atrophy, presence of conjugated hyperbilirubinemia, presence of moderate cerebral cortical atrophy, postural instability detected were noted. Further imaging and laboratory tests identified gene variant T251I/P587L and R807C. The patient was started on a tailored therapeutic plan.
A medical history of sudden focal motor status epilepticus condition was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
Upon examination, clinical signs of acute depletion of mitochondrial dna in liver, history of mild acute hepatic failure, diagnosed with episodic cerebral cortical atrophy were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
Initial symptoms included intermittent cerebral cortical atrophy symptoms, diagnosed with episodic postural instability, episodic depletion of mitochondrial dna in liver, moderate unsteady gait. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of sudden ptosis, severe conjugated hyperbilirubinemia. Laboratory evaluations detected gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Clinical monitoring is ongoing.
Upon examination, history of mild acute hepatic failure were noted. Further imaging and laboratory tests identified gene variant p.Arg953Cys. The patient was started on a tailored therapeutic plan.
A medical history of intermittent depletion of mitochondrial dna in liver detected, acute conjugated hyperbilirubinemia symptoms, intermittent acute hepatic failure symptoms was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
A medical history of persistent cerebral cortical atrophy manifestation was documented. Genetic analysis confirmed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 âˆ’ 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Supportive care and follow-up were recommended.
The individual was admitted with complaints of presence of acute cerebral cortical atrophy, postural instability condition, progressive acute hepatic failure symptoms, presence of moderate conjugated hyperbilirubinemia. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
Upon examination, persistent acute hepatic failure detected, intermittent depletion of mitochondrial dna in liver symptoms, intermittent ptosis symptoms, intermittent unsteady gait observed were noted. Further imaging and laboratory tests identified gene variant c.1535A>T p.K512M. The patient was started on a tailored therapeutic plan.
Upon examination, severe unsteady gait manifestation, history of chronic cerebellar atrophy, progressive ptosis manifestation were noted. Further imaging and laboratory tests identified gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. The patient was started on a tailored therapeutic plan.
A medical history of episodic cerebellar atrophy detected, moderate unsteady gait manifestation was documented. Genetic analysis confirmed gene variant c.2243G>C p.Trp748Ser. Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with chronic cerebellar atrophy, intermittent focal motor status epilepticus symptoms, mild unsteady gait observed, clinical signs of episodic postural instability. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
The patient presented to the clinic with postural instability symptoms, acute ptosis condition. Diagnostic workup revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Treatment was initiated accordingly.
The individual was admitted with complaints of acute postural instability manifestation, presence of hepatic failure, intermittent acute hepatic failure condition. Laboratory evaluations detected gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Clinical monitoring is ongoing.
The individual was admitted with complaints of persistent unsteady gait detected, moderate focal motor status epilepticus manifestation. Laboratory evaluations detected gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Clinical monitoring is ongoing.
A medical history of clinical signs of moderate focal motor status epilepticus, clinical signs of chronic conjugated hyperbilirubinemia, progressive hepatic failure detected, progressive unsteady gait detected was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Upon examination, acute depletion of mitochondrial dna in liver detected, history of sudden ptosis, presence of moderate hepatic failure were noted. Further imaging and laboratory tests identified gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. The patient was started on a tailored therapeutic plan.
Upon examination, persistent acute hepatic failure were noted. Further imaging and laboratory tests identified gene variant 1399G>A A467T and 3573G>T K1191N. The patient was started on a tailored therapeutic plan.
Upon examination, episodic focal motor status epilepticus, persistent cerebral cortical atrophy observed, chronic acute hepatic failure symptoms were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of sudden ptosis, progressive cerebellar atrophy condition was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
Initial symptoms included diagnosed with postural instability, severe hepatic failure observed, presence of progressive acute hepatic failure, persistent focal motor status epilepticus. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
Upon examination, severe ptosis condition, focal motor status epilepticus symptoms were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
A medical history of episodic postural instability manifestation, mild hepatic failure observed, moderate focal motor status epilepticus condition, history of intermittent unsteady gait was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
A medical history of history of episodic hepatic failure, presence of acute depletion of mitochondrial dna in liver, history of mild focal motor status epilepticus, clinical signs of acute postural instability was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
Upon examination, clinical signs of severe depletion of mitochondrial dna in liver, clinical signs of persistent hepatic failure, history of chronic ptosis, intermittent cerebral cortical atrophy were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of severe unsteady gait detected, persistent focal motor status epilepticus observed, sudden depletion of mitochondrial dna in liver manifestation, clinical signs of intermittent acute hepatic failure. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
A medical history of clinical signs of chronic focal motor status epilepticus, history of episodic hepatic failure was documented. Genetic analysis confirmed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Supportive care and follow-up were recommended.
The patient presented to the clinic with conjugated hyperbilirubinemia, intermittent cerebellar atrophy detected, moderate postural instability, progressive acute hepatic failure observed. Diagnostic workup revealed gene variant 1868T>G  L623W and 2263A>G K755E. Treatment was initiated accordingly.
Initial symptoms included mild acute hepatic failure condition, intermittent unsteady gait detected. Subsequent investigations showed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of episodic acute hepatic failure, mild hepatic failure condition, diagnosed with sudden depletion of mitochondrial dna in liver was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
Upon examination, mild acute hepatic failure manifestation, progressive hepatic failure manifestation, mild cerebellar atrophy observed were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
Upon examination, severe acute hepatic failure symptoms, history of progressive unsteady gait were noted. Further imaging and laboratory tests identified gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild focal motor status epilepticus manifestation, acute unsteady gait observed, mild conjugated hyperbilirubinemia detected, diagnosed with sudden postural instability. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
Initial symptoms included history of episodic hepatic failure. Subsequent investigations showed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included history of progressive acute hepatic failure, persistent postural instability detected, diagnosed with progressive hepatic failure. Subsequent investigations showed gene variant A467T. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of chronic conjugated hyperbilirubinemia, persistent acute hepatic failure symptoms, diagnosed with persistent cerebellar atrophy, history of episodic postural instability. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
A medical history of acute postural instability detected, diagnosed with moderate cerebellar atrophy was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
The individual was admitted with complaints of episodic unsteady gait observed. Laboratory evaluations detected gene variant p.Arg627Gln and p.Arg852Cys. Clinical monitoring is ongoing.
The patient presented to the clinic with conjugated hyperbilirubinemia, clinical signs of intermittent cerebral cortical atrophy, intermittent depletion of mitochondrial dna in liver, intermittent hepatic failure observed. Diagnostic workup revealed gene variant p.Arg953Cys. Treatment was initiated accordingly.
Upon examination, acute unsteady gait manifestation, presence of mild postural instability, ptosis detected were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with moderate hepatic failure. Diagnostic workup revealed gene variant 1399G >A A467T and 2243G >C W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of intermittent focal motor status epilepticus detected, severe cerebellar atrophy symptoms, moderate unsteady gait. Laboratory evaluations detected gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Clinical monitoring is ongoing.
A medical history of conjugated hyperbilirubinemia, sudden depletion of mitochondrial dna in liver symptoms was documented. Genetic analysis confirmed gene variant c.1288A>T and c.2752T>C. Supportive care and follow-up were recommended.
A medical history of presence of sudden hepatic failure, chronic unsteady gait observed, progressive acute hepatic failure condition was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Upon examination, moderate cerebral cortical atrophy detected were noted. Further imaging and laboratory tests identified gene variant C752T (T251I) and C1760T (P587L). The patient was started on a tailored therapeutic plan.
A medical history of sudden cerebellar atrophy symptoms, progressive conjugated hyperbilirubinemia manifestation, intermittent ptosis manifestation was documented. Genetic analysis confirmed gene variant W748S. Supportive care and follow-up were recommended.
Upon examination, chronic conjugated hyperbilirubinemia detected, clinical signs of intermittent hepatic failure, diagnosed with chronic unsteady gait, sudden cerebellar atrophy detected were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
A medical history of sudden acute hepatic failure detected, clinical signs of acute cerebellar atrophy, presence of severe postural instability was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
The patient presented to the clinic with severe focal motor status epilepticus observed, history of severe unsteady gait, history of chronic hepatic failure, presence of episodic conjugated hyperbilirubinemia. Diagnostic workup revealed gene variant p.Arg953Cys. Treatment was initiated accordingly.
The individual was admitted with complaints of sudden acute hepatic failure condition. Laboratory evaluations detected gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Clinical monitoring is ongoing.
Upon examination, chronic ptosis manifestation, presence of chronic depletion of mitochondrial dna in liver, history of intermittent hepatic failure were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
Initial symptoms included episodic unsteady gait condition. Subsequent investigations showed gene variant c.1535A>T p.K512M. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included progressive depletion of mitochondrial dna in liver manifestation, presence of focal motor status epilepticus, moderate unsteady gait observed. Subsequent investigations showed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of mild focal motor status epilepticus condition, chronic ptosis manifestation, presence of progressive hepatic failure. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
The individual was admitted with complaints of severe hepatic failure observed, presence of progressive ptosis, persistent depletion of mitochondrial dna in liver symptoms, presence of mild unsteady gait. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
The individual was admitted with complaints of episodic depletion of mitochondrial dna in liver. Laboratory evaluations detected gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Clinical monitoring is ongoing.
Upon examination, progressive cerebellar atrophy detected, history of moderate acute hepatic failure, severe focal motor status epilepticus manifestation were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with intermittent postural instability. Diagnostic workup revealed gene variant p.Arg953Cys. Treatment was initiated accordingly.
